Decitabine in Treating Patients With Myelofibrosis

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 80 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv80
  2. Study completion date: Feb 22, 2026 to Feb 22, 2027v79
  3. Re-verified, no change to tracked fieldsv78
  4. Study completion date: Feb 22, 2025 to Feb 22, 2026v77
  5. 2 versions Re-verified since Aug 23, 2024, no change to tracked fieldsv75-v76
Show 44 earlier versionsHide 44 earlier versions
  1. Study completion date: Feb 22, 2025v74
  2. 14 versions Re-verified since Nov 7, 2019, no change to tracked fieldsv60-v73
  3. Study sites revised (14)v59
  4. 13 versions Re-verified since Jun 15, 2017, no change to tracked fieldsv46-v58
  5. Primary completion date: Jul 2008 to Jul 1, 2008
    • Start date: Sep 2004 to Sep 29, 2004
    v45
  6. 4 versions Re-verified since Aug 15, 2016, no change to tracked fieldsv41-v44
  7. Study sites revised (14)v40
  8. Re-verified, no change to tracked fieldsv39
  9. Study sites: 11 to 14
    • Interventions: decitabine (Drug) to Decitabine (Drug), Laboratory Biomarker Analysis (Other)
    • Eligibility criteria expanded, about 276 words
    • Study description expanded, about 66 words
    v38
  10. Results first posted: Jan 5, 2015
    • Primary endpoints revised (2)
    • Enrollment target: estimated 20 to confirmed 21
    • Secondary endpoints expanded, about 30 words
    v37
  11. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Jan 2100 to Jul 2008
    • Site details revised at 11 of 11 sites
    v36
  12. Lead sponsor: University of Chicago to National Cancer Institute (NCI)v35 Show 7 more changesShow less
    • Primary completion date: Jul 2005 to Jan 2100
    • Primary endpoints revised (2)
    • Eligibility criteria shortened, about 45 words
    • Study description shortened, about 14 words
    • Study sites revised (11)
    • Study arms: 0 to 1
    • Collaborators shortened, about 4 words
  13. Site contacts updated at 1 of 11 sitesv34
  14. Site contacts updated at 1 of 11 sitesv33
  15. Re-verified, no change to tracked fieldsv32
  16. Study sites revised (11)v31
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the side effects and how well decitabine works in treating patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar tissue) in the bone marrow that is advanced and for which there is no standard therapy. Decitabine may block the actions of some proteins that are responsible for turning certain genes off in various cancers including myelofibrosis.
Trial Details
NCT Number NCT00095784
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Primary Myelofibrosis, Secondary Myelofibrosis
Related terms Primary Myelofibrosis
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov